In a systematic review, pneumonitis occurred in 4% of patients receiving PD-(L)1 inhibitors (1% grade ≥ 3) and in 1% of patients receiving anti-CTLA-4 therapy (1% grade ≥ 3) [22]. Here, CTLA4 is linked to pneumonitis.